

1

decade

of MMV mission working in partnership  
to discover, develop and facilitate  
access to new medicines for malaria

**140**  
partners

**45**  
countries

# 50

projects including:

## 2

medicines  
launched

## 2

medicines  
undergoing  
regulatory  
approval

## 2

medicines  
currently  
in clinical  
studies

## 2

compounds  
that will enter  
clinical studies  
by year-end

2

medicines  
launched

65

million courses delivered  
**Coartem-dispersible**  
*MMV / Novartis*

128 000

paediatric treatment courses  
**Injected artesunate**  
*MMV / Guillin*

160 000

children's lives saved

9 000

children's lives saved

1

child dies  
every

45

seconds  
from malaria



## areas of strategic focus over the next 5 years

improved  
access  
to ACTs

treatments  
for children  
and pregnant  
women

single-dose  
medicines

medicines  
to pre-empt  
artemisinin  
resistance

medicines that  
facilitate malaria  
elimination and  
eradication

## Agenda

- Global plan for artemisinin resistance containment
- Medicines and the elimination of malaria
- Medicines for protection during pregnancy
- DHA/PQP: once-per-day treatment for uncomplicated malaria
- Artesunate injection: for management of severe malaria
- DHODH: structure based design of a new class of drugs

Thank you for your continued support

“I’m a patient investor”

Bill Gates

“The UK will not balance  
its books on the backs  
of the poorest”

David Cameron  
British Prime Minister